What's in Shineway Pharmaceutical Co.,Ltd's pipeline?

Shineway Pharmaceutical Co.,Ltd has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Shineway Pharmaceutical Co.,Ltd's portfolio?

Top competitors by shared drug class: Beijing Tiantan Hospital, Tasly Pharmaceuticals, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shineway-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Shineway Pharmaceutical Co.,Ltd — Portfolio Competitive Intelligence Brief

Shineway Pharmaceutical Co.,Ltd pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
the control group	the control group	marketed
SaiLuoTong capsule	SaiLuoTong capsule	phase 3	Traditional Chinese medicine compound		Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Beijing Tiantan Hospital · 1 shared drug class
Tasly Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shineway Pharmaceutical Co.,Ltd:

Cite this brief

Drug Landscape (2026). Shineway Pharmaceutical Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shineway-pharmaceutical-co-ltd. Accessed 2026-05-16.